Karyopharm Therapeut (KPTI)

$5.68 +0.18 (3.27%)
Market Cap 93.78M
Revenue (ttm) 145.24M
Net Income (ttm) -76.42M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -52.62%
Debt to Equity Ratio -0.36
Volume 95,300
Avg Vol 186,358
Day's Range N/A - N/A
Shares Out 17.05M
Stochastic %K 68%
Beta 0.35
Analysts Strong Sell
Price Target $14.00

Company Profile

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for th...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 658 0600
Address:
85 Wells Avenue, 2nd Floor, Suite 210, Newton, United States
celebratelife
celebratelife Nov. 14 at 5:51 PM
$KPTI [CORRECTION] JPM's latest filing shows they own about 430k shares. Their hedge fund High Bridge Capital beneficiary owns about 650k shares.
0 · Reply
celebratelife
celebratelife Nov. 14 at 5:41 PM
$KPTI New 5% owner JPM's High Bridge Capital https://x.com/karyowatch/status/1989387875511910890
1 · Reply
celebratelife
celebratelife Nov. 13 at 8:20 PM
$KPTI Richard Paulson is a dream CEO for short sellers. https://x.com/karyowatch/status/1989065554318225675
1 · Reply
celebratelife
celebratelife Nov. 13 at 7:07 PM
$KPTI McDreamy's the winner, at our cost: https://x.com/karyowatch/status/1983186459818635580
0 · Reply
celebratelife
celebratelife Nov. 12 at 5:08 PM
$KPTI Paulson's idea of financial discipline: https://x.com/karyowatch/status/1988654925614809117
0 · Reply
laaarsas
laaarsas Nov. 11 at 5:50 AM
$KPTI does anyone here know exactly how the Abs-TSS will be measured? What measure will they use? And what is the expected effect size?
0 · Reply
laaarsas
laaarsas Nov. 11 at 3:05 AM
$KPTI AI tells me Abs-TSS needs to be improved by at least 4-5 points. Which is more than double from what competitors have managed. I don't see how this would be possible. What do you think?
1 · Reply
laaarsas
laaarsas Nov. 11 at 2:25 AM
$KPTI is the fact that this drug makes a lot of patients throw up a huge drawback that will not make this sell much?
1 · Reply
laaarsas
laaarsas Nov. 11 at 2:09 AM
$KPTI so they have revenue of about 30-40M per Q, and expenses of around 50-60M, resulting in 10-20M loss every quarter. What could make this company profitable?
0 · Reply
laaarsas
laaarsas Nov. 10 at 10:25 PM
$KPTI what is going on here?
0 · Reply
Latest News on KPTI
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 3, 2025, 4:05 PM EST - 11 days ago

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm Therapeutics Inc. (KPTI) Q3 2025 Earnings Call Transcript

Nov 3, 2025, 1:26 PM EST - 11 days ago

Karyopharm Therapeutics Inc. (KPTI) Q3 2025 Earnings Call Transcript

Karyopharm Reports Third Quarter 2025 Financial Results and Highlights Recent Company Progress

Nov 3, 2025, 7:00 AM EST - 11 days ago

Karyopharm Reports Third Quarter 2025 Financial Results and Highlights Recent Company Progress

Karyopharm to Report Third Quarter 2025 Financial Results on November 3, 2025

Oct 27, 2025, 7:00 AM EDT - 18 days ago

Karyopharm to Report Third Quarter 2025 Financial Results on November 3, 2025

Karyopharm Strengthens Balance Sheet With $100 Million Financing To Extend Cash Runway Into 2026

Oct 8, 2025, 1:31 PM EDT - 5 weeks ago

Karyopharm Strengthens Balance Sheet With $100 Million Financing To Extend Cash Runway Into 2026

Karyopharm Announces Strategic Financing Transactions to Support Growth; Extends Cash Runway Into Second Quarter of 2026, Beyond Expected Top-Line Readout of Phase 3 SENTRY Trial in Myelofibrosis

Oct 8, 2025, 7:00 AM EDT - 5 weeks ago

Karyopharm Announces Strategic Financing Transactions to Support Growth; Extends Cash Runway Into Second Quarter of 2026, Beyond Expected Top-Line Readout of Phase 3 SENTRY Trial in Myelofibrosis

Karyopharm Announces Completion of Enrollment in the Phase 3 SENTRY Trial in Myelofibrosis

Sep 10, 2025, 7:00 AM EDT - 2 months ago

Karyopharm Announces Completion of Enrollment in the Phase 3 SENTRY Trial in Myelofibrosis

Karyopharm Therapeutics Inc. (KPTI) Q2 2025 Earnings Call Transcript

Aug 11, 2025, 11:02 AM EDT - 3 months ago

Karyopharm Therapeutics Inc. (KPTI) Q2 2025 Earnings Call Transcript

Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company Progress

Aug 11, 2025, 7:30 AM EDT - 3 months ago

Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company Progress

Karyopharm to Report Second Quarter 2025 Financial Results on August 11, 2025

Aug 5, 2025, 7:00 AM EDT - 3 months ago

Karyopharm to Report Second Quarter 2025 Financial Results on August 11, 2025

Karyopharm to Present at the Jefferies Global Healthcare Conference

Jun 3, 2025, 8:00 AM EDT - 5 months ago

Karyopharm to Present at the Jefferies Global Healthcare Conference

Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference

May 19, 2025, 7:00 AM EDT - 6 months ago

Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference

Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting

May 14, 2025, 9:31 AM EDT - 6 months ago

Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting

These Analysts Revise Their Forecasts On Karyopharm Therapeutics After Q1 Results

May 13, 2025, 1:39 PM EDT - 6 months ago

These Analysts Revise Their Forecasts On Karyopharm Therapeutics After Q1 Results

Karyopharm Therapeutics Inc. (KPTI) Q1 2025 Earnings Call Transcript

May 13, 2025, 7:15 AM EDT - 6 months ago

Karyopharm Therapeutics Inc. (KPTI) Q1 2025 Earnings Call Transcript

Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease Modification

May 12, 2025, 4:05 PM EDT - 6 months ago

Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease Modification

Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025

May 8, 2025, 4:05 PM EDT - 6 months ago

Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025

XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC

Mar 5, 2025, 12:00 AM EST - 9 months ago

XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC

Karyopharm Announces 1-for-15 Reverse Stock Split

Feb 24, 2025, 8:40 AM EST - 9 months ago

Karyopharm Announces 1-for-15 Reverse Stock Split

Karyopharm Therapeutics Inc. (KPTI) Q4 2024 Earnings Call Transcript

Feb 19, 2025, 11:05 AM EST - 9 months ago

Karyopharm Therapeutics Inc. (KPTI) Q4 2024 Earnings Call Transcript

Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress

Feb 19, 2025, 7:30 AM EST - 9 months ago

Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress

Antengene Announces XPOVIO® Approved for Public Health Insurance Coverage in Taiwan Market, Benefiting More Patients with R/R MM in the Region

Feb 13, 2025, 4:30 AM EST - 9 months ago

Antengene Announces XPOVIO® Approved for Public Health Insurance Coverage in Taiwan Market, Benefiting More Patients with R/R MM in the Region

Karyopharm to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025

Feb 12, 2025, 7:00 AM EST - 9 months ago

Karyopharm to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025

Karyopharm Announces Preliminary Unaudited 2024 Revenue and 2025 Objectives

Jan 13, 2025, 8:30 AM EST - 10 months ago

Karyopharm Announces Preliminary Unaudited 2024 Revenue and 2025 Objectives

Karyopharm Announces the Appointment of Lori Macomber as Chief Financial Officer

Jan 2, 2025, 7:00 AM EST - 11 months ago

Karyopharm Announces the Appointment of Lori Macomber as Chief Financial Officer

Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications

Dec 9, 2024, 8:00 AM EST - 1 year ago

Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications

Karyopharm Therapeutics Provides Endometrial Cancer Program Update

Dec 3, 2024, 7:00 AM EST - 1 year ago

Karyopharm Therapeutics Provides Endometrial Cancer Program Update

Karyopharm to Participate at the Piper Sandler 36th Annual Healthcare Conference

Nov 25, 2024, 7:00 AM EST - 1 year ago

Karyopharm to Participate at the Piper Sandler 36th Annual Healthcare Conference

Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer

Nov 20, 2024, 4:05 PM EST - 1 year ago

Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer

Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and Exposition

Nov 18, 2024, 7:00 AM EST - 1 year ago

Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and Exposition

Karyopharm Therapeutics Inc. (KPTI) Q3 2024 Earnings Call Transcript

Nov 5, 2024, 9:22 PM EST - 1 year ago

Karyopharm Therapeutics Inc. (KPTI) Q3 2024 Earnings Call Transcript

Antengene to Present Results from Two Late-Stage Studies of Selinexor Signaling Potential Clinical Breakthrough at ASH 2024

Nov 5, 2024, 7:30 PM EST - 1 year ago

Antengene to Present Results from Two Late-Stage Studies of Selinexor Signaling Potential Clinical Breakthrough at ASH 2024

Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress

Nov 5, 2024, 7:30 AM EST - 1 year ago

Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress

Karyopharm to Report Third Quarter 2024 Financial Results on November 5, 2024

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Karyopharm to Report Third Quarter 2024 Financial Results on November 5, 2024

Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis

Oct 31, 2024, 7:30 AM EDT - 1 year ago

Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis

Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024

Oct 30, 2024, 4:30 PM EDT - 1 year ago

Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024

Antengene Announces XPOVIO® (selinexor) Approved for Its Third Indication in South Korea, Bringing Fresh Hope to Patients with MM in the Country

Oct 17, 2024, 10:35 PM EDT - 1 year ago

Antengene Announces XPOVIO® (selinexor) Approved for Its Third Indication in South Korea, Bringing Fresh Hope to Patients with MM in the Country

Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Thailand

Sep 23, 2024, 5:00 AM EDT - 1 year ago

Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Thailand

Karyopharm to Participate at Upcoming Investor Conferences

Sep 3, 2024, 7:00 AM EDT - 1 year ago

Karyopharm to Participate at Upcoming Investor Conferences

Karyopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress

Aug 6, 2024, 7:30 AM EDT - 1 year ago

Karyopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress

Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Malaysia

Aug 5, 2024, 8:00 PM EDT - 1 year ago

Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Malaysia

Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024

Jul 31, 2024, 4:05 PM EDT - 1 year ago

Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024

XPOVIO® (selinexor) Approved for New Indication in DLBCL in China, Bringing a New Treatment Option to Patients in the Country

Jul 5, 2024, 9:10 AM EDT - 1 year ago

XPOVIO® (selinexor) Approved for New Indication in DLBCL in China, Bringing a New Treatment Option to Patients in the Country

Antengene Announces XPOVIO® (selinexor) National Health Insurance Service Approval for Reimbursement in South Korea

Jun 26, 2024, 4:42 AM EDT - 1 year ago

Antengene Announces XPOVIO® (selinexor) National Health Insurance Service Approval for Reimbursement in South Korea

Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates

Jun 1, 2024, 1:45 PM EDT - 1 year ago

Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates

Karyopharm to Participate at the Jefferies Global Healthcare Conference

May 29, 2024, 4:05 PM EDT - 1 year ago

Karyopharm to Participate at the Jefferies Global Healthcare Conference

Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare Conference

May 8, 2024, 4:05 PM EDT - 1 year ago

Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare Conference

Karyopharm Therapeutics Inc. (KPTI) Q1 2024 Earnings Call Transcript

May 8, 2024, 3:38 PM EDT - 1 year ago

Karyopharm Therapeutics Inc. (KPTI) Q1 2024 Earnings Call Transcript

Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029

May 8, 2024, 7:30 AM EDT - 1 year ago

Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029

Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress

May 8, 2024, 7:30 AM EDT - 1 year ago

Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress

celebratelife
celebratelife Nov. 14 at 5:51 PM
$KPTI [CORRECTION] JPM's latest filing shows they own about 430k shares. Their hedge fund High Bridge Capital beneficiary owns about 650k shares.
0 · Reply
celebratelife
celebratelife Nov. 14 at 5:41 PM
$KPTI New 5% owner JPM's High Bridge Capital https://x.com/karyowatch/status/1989387875511910890
1 · Reply
celebratelife
celebratelife Nov. 13 at 8:20 PM
$KPTI Richard Paulson is a dream CEO for short sellers. https://x.com/karyowatch/status/1989065554318225675
1 · Reply
celebratelife
celebratelife Nov. 13 at 7:07 PM
$KPTI McDreamy's the winner, at our cost: https://x.com/karyowatch/status/1983186459818635580
0 · Reply
celebratelife
celebratelife Nov. 12 at 5:08 PM
$KPTI Paulson's idea of financial discipline: https://x.com/karyowatch/status/1988654925614809117
0 · Reply
laaarsas
laaarsas Nov. 11 at 5:50 AM
$KPTI does anyone here know exactly how the Abs-TSS will be measured? What measure will they use? And what is the expected effect size?
0 · Reply
laaarsas
laaarsas Nov. 11 at 3:05 AM
$KPTI AI tells me Abs-TSS needs to be improved by at least 4-5 points. Which is more than double from what competitors have managed. I don't see how this would be possible. What do you think?
1 · Reply
laaarsas
laaarsas Nov. 11 at 2:25 AM
$KPTI is the fact that this drug makes a lot of patients throw up a huge drawback that will not make this sell much?
1 · Reply
laaarsas
laaarsas Nov. 11 at 2:09 AM
$KPTI so they have revenue of about 30-40M per Q, and expenses of around 50-60M, resulting in 10-20M loss every quarter. What could make this company profitable?
0 · Reply
laaarsas
laaarsas Nov. 10 at 10:25 PM
$KPTI what is going on here?
0 · Reply
celebratelife
celebratelife Nov. 10 at 2:44 PM
$KPTI Something our clowns Richard Paulson, Mike Mano, Barry Greene, and SOME of the Board members don't understand: https://x.com/karyowatch/status/1987893245016522965
0 · Reply
laaarsas
laaarsas Nov. 10 at 2:19 AM
$KPTI ppl hate management? Why? What ppl think bout upcoming phase 3 trials?
1 · Reply
celebratelife
celebratelife Nov. 9 at 10:53 PM
$KPTI Hay in Richard Paulson's skull or is he compromised? https://x.com/karyowatch/status/1987654004089004459
0 · Reply
celebratelife
celebratelife Nov. 9 at 4:00 PM
$KPTI Sharon Shacham knows how great the drug is: https://x.com/karyowatch/status/1987550124617482405
0 · Reply
celebratelife
celebratelife Nov. 9 at 3:43 PM
$KPTI One of the ways the evil CEO &BoD have destroyed our assets: https://x.com/karyowatch/status/1987545693398151451
0 · Reply
celebratelife
celebratelife Nov. 9 at 6:58 AM
$KPTI Picture of Evil Richard Paulson destroying our assets / compromising runway: https://x.com/karyowatch/status/1987414148842725706
0 · Reply
celebratelife
celebratelife Nov. 8 at 7:04 PM
$KPTI Paulson's mismanagement is the cause of KPTI decimation. He's having a great weekend: https://x.com/karyowatch/status/1987234126001545436
0 · Reply
celebratelife
celebratelife Nov. 8 at 6:43 PM
$KPTI Richard Paulson is Karyopharm's Cancer: https://x.com/karyowatch/status/1987229434462806235
0 · Reply
celebratelife
celebratelife Nov. 8 at 6:23 PM
$KPTI Why Richard Paulson is an evil man, in my opinion: https://x.com/karyowatch/status/1987223781916688470
0 · Reply
laaarsas
laaarsas Nov. 7 at 4:00 PM
$KPTI what people think here? Strong case for success in phase 3 trials?
0 · Reply
laaarsas
laaarsas Nov. 7 at 2:29 PM
$KPTI what do people feel about this post-hoc case?
0 · Reply
SunriseMorning
SunriseMorning Nov. 7 at 12:35 AM
$KPTI is it everyday red. holding a bag
0 · Reply